OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC

15 Apr 20264 min read0 viewsJournal Feed

GIST

Nature Reviews Clinical Oncology, Published online: 15 April 2026; doi:10.1038/s41571-026-01150-1 OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC

Clinical Editorial

Summary

Nature Reviews Clinical Oncology published a clinical update in Oncology on 15 Apr 2026. The item focuses on OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC. Open the detail page to review the full original feed content.